Skip to main content
NCBI home page
Journal of Clinical Microbiology logoLink to Journal of Clinical Microbiology
. 1989 Apr;27(4):640–643. doi: 10.1128/jcm.27.4.640-643.1989

Functional capacity of immunoglobulin G preparations and the F(ab')2 split product.

R W Steele 1, R W Steele 1
PMCID: PMC267388  PMID: 2723032

Abstract

Five immunoglobulin G preparations, including one 5S F(ab')2 split product, were compared for activity against common bacterial, viral, and protozoan pathogens. Standard assays were used to quantitate antibodies to tetanus, diphtheria, cytomegalovirus, herpes simplex virus types 1 and 2, rubella virus, and Toxoplasma gondii. Opsonization and killing of bacteria were examined by chemiluminescence methods using Streptococcus pneumoniae types 5, 12F, and 14 and Staphylococcus aureus. Antibodies to the viral pathogens and T. gondii were not detectable for the 5S immunoglobulin even at high concentrations (50 mg/ml) but were present in all 7S preparations at immunoglobulin concentrations of 10 mg/ml. Relatively lower activities for tetanus and diphtheria antibody were also seen with the F(ab')2 product. Opsonizing capacity against all pneumococcal serotypes and Staphylococcus aureus was lowest for the 5S product and highest for the commercially available intravenous immunoglobulin product that is purified by using a pH 4.25 formulation. These data do not support potential clinical usefulness of immunoglobulin G split products and suggest wide variations of specific antibody among commercial intravenous immunoglobulin preparations.

Full text

PDF
640

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allen R. C. Evaluation of serum opsonic capacity by quantitating the initial chemiluminescent response from phagocytizing polymorphonuclear leukocytes. Infect Immun. 1977 Mar;15(3):828–833. doi: 10.1128/iai.15.3.828-833.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Ax W., Kanzy E. J., Seiler F. R. In-vivo phagocytosis: enhancement of bacterial clearance by native and enzyme-treated immunoglobulins. Immunobiology. 1981;159(4-5):349–365. doi: 10.1016/S0171-2985(81)80092-7. [DOI] [PubMed] [Google Scholar]
  3. BOYDEN S. V. The adsorption of proteins on erythrocytes treated with tannic acid and subsequent hemagglutination by antiprotein sera. J Exp Med. 1951 Feb;93(2):107–120. doi: 10.1084/jem.93.2.107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Blanchard G. C., Gardner R. Two nephelometric methods compared with a radial immunodiffusion method for the measurement of IgG, IgA and IgM. Clin Biochem. 1980 Apr;13(2):84–91. doi: 10.1016/s0009-9120(80)91253-9. [DOI] [PubMed] [Google Scholar]
  5. Chehimi J., Peppard J., Emanuel D. Selection of an intravenous immune globulin for the immunoprophylaxis of cytomegalovirus infections: an in vitro comparison of currently available and previously effective immune globulins. Bone Marrow Transplant. 1987 Dec;2(4):395–402. [PubMed] [Google Scholar]
  6. Davis S. D. Efficacy of modified human immune serum globulin in the treatment of experimental murine infections with seven immunotypes of Pseudomonas aeruginosa. J Infect Dis. 1975 Jun;131(6):717–721. doi: 10.1093/infdis/131.6.717. [DOI] [PubMed] [Google Scholar]
  7. Johannsen R., Kanzy E. J., Ackerman O., Barth R., Bengelsdorff H. J., Hinz J., Weinmann E., Gruschkau H., Seiler F. R. Schutzwirkung von unmodifizierten und S-sulfonierten 7S-Antikörpern bei 4 verschiedenen experimentellen Virusinfektionen. Beitr Infusionther Klin Ernahr. 1982;9:141–154. [PubMed] [Google Scholar]
  8. Morgan E. L., Tempelis C. H. The requirement for the Fc portion of antibody in antigen-antibody complex-mediated suppression. J Immunol. 1978 May;120(5):1669–1671. [PubMed] [Google Scholar]
  9. Ochs H. R., Vatner S. F., Smith T. W. Reversal of inotropic effects of digoxin by specific antibodies and their Fab fragments in the conscious dog. J Pharmacol Exp Ther. 1978 Oct;207(1):64–71. [PubMed] [Google Scholar]
  10. Sedlacek H. H., Gronski P., Hofstaetter T., Kanzy E. J., Schorlemmer H. U., Seiler F. R. The biological properties of immunoglobulin G and its split products [F(ab')2 and Fab]. Klin Wochenschr. 1983 Aug 1;61(15):723–736. doi: 10.1007/BF01497399. [DOI] [PubMed] [Google Scholar]
  11. Steele R. W., Augustine R. A., Steele R. W., Tannenbaum A. S., Charlton R. K. A comparison of native and modified intravenous immunoglobulin for the management of hypogammaglobulinemia. Am J Med Sci. 1987 Feb;293(2):69–74. doi: 10.1097/00000441-198702000-00001. [DOI] [PubMed] [Google Scholar]
  12. Steele R. W., Burks A. W., Jr, Williams L. W. Intravenous immunoglobulin: new clinical applications. Ann Allergy. 1988 Feb;60(2):89–94. [PubMed] [Google Scholar]
  13. Trautmann M., Müller-Leutloff Y., Hofstaetter T., Seiler F. R., Hahn H. In vitro and in vivo activities of different immunoglobulin G preparations from the rabbit against Enterobacteriaceae. Vox Sang. 1985;49(4):267–276. doi: 10.1111/j.1423-0410.1985.tb01121.x. [DOI] [PubMed] [Google Scholar]
  14. Zartarian M. V., Friedly G., Peterson E. M., de la Maza L. M. Detection of rubella antibodies by hemagglutination inhibition, indirect fluorescent-antibody test, and enzyme-linked immunosorbent assay. J Clin Microbiol. 1981 Dec;14(6):640–645. doi: 10.1128/jcm.14.6.640-645.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES